Caribou Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 89.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2026-03-05
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2025-03-31 was 89.70%, a 18.18% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2024-03-31 was 75.90%.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-09-30 was 74.60%.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2023-06-30 was 74.80%.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2025 was 89.90%, a 18.45% increase from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 75.90%, a 0.13% increase from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 75.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|---|---|
| 2025-12-31 | 89.90% 10-K · filed 2026-03-05 | |||
| 2025-06-30 | 89.70% 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 89.70% 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 75.90% 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 75.90% 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | 75.90% 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 75.90% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 75.80% 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 74.60% 10-Q · filed 2024-11-06 | 75.00% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 74.80% 10-Q · filed 2024-08-06 | 75.00% 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |